Oxidative Stress in Alzheimer Disease

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2009 Apr 18

PMID 19372765

Citations 157

Authors

Alejandro Gella

Nuria Durany

Affiliations

Soon will be listed here.

Abstract

Alzheimer disease (AD) is a progressive dementia affecting a large proportion of the aging population. The histopathological changes in AD include neuronal cell death, formation of amyloid plaques and neurofibrillary tangles. There is also evidence that brain tissue in patients with AD is exposed to oxidative stress (e.g., protein oxidation, lipid oxidation, DNA oxidation and glycoxidation) during the course of the disease. Advanced glycation endproducts (AGEs) are present in amyloid plaques in AD, and its extracellular accumulation may be caused by an accelerated oxidation of glycated proteins. AGEs participate in neuronal death causing direct (chemical) and indirect (cellular) free radical production and consequently increase oxidative stress. The development of drugs for the treatment of AD that breaks the vicious cycles of oxidative stress and neurodegeneration offer new opportunities. These approaches include AGE-inhibitors, antioxidants and anti-inflammatory substances, which prevent free radical production.

Citing Articles

Network pharmacology and metabolomics analysis of Tinospora cordifolia reveals BACE1 and MAOB as potential therapeutic targets for neuroprotection in Alzheimer's disease.

Amrutha S, Abhinand C, Upadhyay S, Parvaje R, Prasad T, Modi P Sci Rep. 2025; 15(1):8103.

PMID: 40057579 PMC: 11890609. DOI: 10.1038/s41598-025-92756-5.

Development of cerebral microhemorrhages in a mouse model of hypertension.

Xie D, Fang C, Crouzet C, Hung Y, Vallejo A, Lee D J Neuroinflammation. 2025; 22(1):67.

PMID: 40045320 PMC: 11881401. DOI: 10.1186/s12974-025-03378-7.

Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications.

Dash U, Bhol N, Swain S, Samal R, Nayak P, Raina V Acta Pharm Sin B. 2025; 15(1):15-34.

PMID: 40041912 PMC: 11873663. DOI: 10.1016/j.apsb.2024.10.004.

Scopolamine-induced memory impairment in mice: Soursop leaf extract and fractions protect the hippocampus and prefrontal cortex.

Afolabi F, Alabi B, Badejo J, Nsor O, Lawal S, Iwalewa E Iran J Basic Med Sci. 2025; 28(3):355-365.

PMID: 39906616 PMC: 11790190. DOI: 10.22038/ijbms.2024.80289.17379.

Insufficient Sleep and Alzheimer's Disease: Potential Approach for Therapeutic Treatment Methods.

Trinh D, Mai N, Pham T Brain Sci. 2025; 15(1).

PMID: 39851389 PMC: 11763454. DOI: 10.3390/brainsci15010021.

References

Thome J, Kornhuber J, Munch G, Schinzel R, Taneli Y, ZIELKE B . [New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs)]. Nervenarzt. 1996; 67(11):924-9. DOI: 10.1007/s001150050073. View

White A, Barnham K, Bush A . Metal homeostasis in Alzheimer's disease. Expert Rev Neurother. 2006; 6(5):711-22. DOI: 10.1586/14737175.6.5.711. View

Rosler M, Retz W, Thome J, Riederer P . Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl. 1998; 54:211-9. DOI: 10.1007/978-3-7091-7508-8_21. View

Yen S, Liu W, Hall F, Yan S, Stern D, Dickson D . Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging. 1995; 16(3):381-7. DOI: 10.1016/0197-4580(95)00022-7. View

Hamilton M, Van Remmen H, Drake J, Yang H, Guo Z, Kewitt K . Does oxidative damage to DNA increase with age?. Proc Natl Acad Sci U S A. 2001; 98(18):10469-74. PMC: 56984. DOI: 10.1073/pnas.171202698. View

Smith M, Sayre L, Anderson V, Harris P, Beal M, Kowall N . Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem. 1998; 46(6):731-5. DOI: 10.1177/002215549804600605. View

Mattson M, Chan S . Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium. 2003; 34(4-5):385-97. DOI: 10.1016/s0143-4160(03)00128-3. View

Chen T, Richie Jr J, LANG C . The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc Soc Exp Biol Med. 1989; 190(4):399-402. DOI: 10.3181/00379727-190-42879. View

Mecocci P, MacGarvey U, Beal M . Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994; 36(5):747-51. DOI: 10.1002/ana.410360510. View

10.

Curb J, Rodriguez B, Abbott R, Petrovitch H, Ross G, Masaki K . Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999; 52(5):971-5. DOI: 10.1212/wnl.52.5.971. View

11.

Gabbita S, Lovell M, Markesbery W . Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem. 1998; 71(5):2034-40. DOI: 10.1046/j.1471-4159.1998.71052034.x. View

12.

Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I . Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem. 1995; 64(3):1216-23. DOI: 10.1046/j.1471-4159.1995.64031216.x. View

13.

Staehelin H . Micronutrients and Alzheimer's disease. Proc Nutr Soc. 2005; 64(4):565-70. DOI: 10.1079/pns2005459. View

14.

Gsell W, Strein I, Krause U, Riederer P . Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review. J Neural Transm Suppl. 1997; 51:145-59. View

15.

Zhu Y, Carvey P, Ling Z . Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res. 2006; 1090(1):35-44. PMC: 1868496. DOI: 10.1016/j.brainres.2006.03.063. View

16.

Perrig W, Perrig P, Stahelin H . The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc. 1997; 45(6):718-24. DOI: 10.1111/j.1532-5415.1997.tb01476.x. View

17.

Ortwerth B, Olesen P . Ascorbic acid-induced crosslinking of lens proteins: evidence supporting a Maillard reaction. Biochim Biophys Acta. 1988; 956(1):10-22. DOI: 10.1016/0167-4838(88)90292-0. View

18.

Selley M, Close D, Stern S . The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002; 23(3):383-8. DOI: 10.1016/s0197-4580(01)00327-x. View

19.

Barnham K, Masters C, Bush A . Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004; 3(3):205-14. DOI: 10.1038/nrd1330. View

20.

Keller J, Pang Z, Geddes J, Begley J, Germeyer A, Waeg G . Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem. 1997; 69(1):273-84. DOI: 10.1046/j.1471-4159.1997.69010273.x. View